AK
Anne Marijn Kramer
Amsterdam UMC Location Vrije Universiteit Amsterdam, Stanford University, University College London, Johan van Oldenbarnevelt gymnasium, Amsterdam UMC Location University of Amsterdam
Research areas: Immunology and Microbiology · Immunology · CAR-T cell therapy research · T-cell and B-cell Immunology · Immunotherapy and Immune Responses
0000-0001-5239-7343
Employment
-
Amsterdam UMC Location VUmc Postdoctoral fellow2025 - Present
-
Stanford University Postdoc2022 - Present
-
Academic Medical Center Resident2019 - 2022
-
Tergooi Resident2017 - 2018
Education
- 2014 - 2017
-
Johan van Oldenbarnevelt gymnasium Natuur en Gezondheid, Cum laude1999 - 2005
-
Academic Medical Center MD, cum laude? - 2013
Projects & Funding
-
Study of CAR T-Cell Associated Toxicity and Efficacy: Mechanisms, Clinicopathologic Correlates, and state-of-the-art nanomedicine-based targeting of myeloid immune cells as a novel therapeutic strategy European Hematology Association2022 - 2025
-
Study of CAR T-Cell Associated Toxicity and Efficacy: Mechanisms, Clinicopathologic Correlates, and state-of-the-art nanomedicine-based targeting of myeloid immune cells as a novel therapeutic strategy Stichting Lymph&Co2022 - 2024
Publications (77)
- Figure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S10 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S11 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S8 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Figure S9 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Table S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Table S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Table S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Table S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Table S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Table S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Table S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome Save
- Data from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome Save